Nasus PharmaNSRX
13F holders, Q1 2026 (March 31)9holders +7
7new positions
0sold out
$2.22avg. 13F price*
At the end of Q1 2026, 9 institutions reported holding Nasus Pharma Ltd. (NSRX) in their 13F filings, up 7 from Q4 2025. 7 opened new positions and 0 sold out. The largest holders were Balyasny Asset Management L.P. ($2.0M), Cable Car Capital, LP ($1.3M) and Velan Capital Investment Management LP ($798K).
- Company
- Nasus Pharma Ltd.
- CUSIP
- M7071P109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $4.8M |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 2,171,896 shares bought, net +2,171,896 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Balyasny Asset Management L.P. | 0.00% | New | 898,473 | $2.0M |
| Cable Car Capital, LP | 0.57% | New | 601,998 | $1.3M |
| Velan Capital Investment Management LP | 0.50% | New | 359,390 | $798K |
| Hudson Bay Capital Management LP | 0.00% | New | 134,771 | $299K |
| Bleichroeder LP | 0.03% | New | 89,848 | $199K |
| Empery Asset Management, LP | 0.12% | New | 45,803 | $102K |
| HRT Financial LP | 0.00% | New | 38,897 | $86K |
| UBS Group AG | 0.00% | Add +718.5% | 3,094 | $7K |
| Morgan Stanley | 0.00% | No change | 2,000 | $4K |
"% of holder's portfolio" is NSRX's weight in each manager's 13F, not the share of Nasus Pharma Ltd. the manager owns.